A sustained release cisapride oral dosage formulation suitable for once-dailyadministration comprises a plurality of mini-tablets containing cisapride or asalt thereof with an organic acid and capable or releasing cisapride atdifferent sites along the gastrointestinal tract. The mini-tablets include aproportion of immediate release tablets and a proportion of tablets whichrelease cisapride in response to the pH environment at a given site in thedistal regions of the gastrointestinal tract and which include cisapride or asalt thereof embedded in a matrix of hydrophilic polymer, said matrix beingcoated with a pH dependent polymer, the formulation having a Cmax/Cmin ratiounder steady state conditions of 2:1 or less as evidenced by a substantiallyflat plasma profile in vivo.
展开▼
